leisure time -WSS

leisure time

author：fashion 2025-09-29 21:20:57 - browse：9

Adobe

At least 224 diabetes patients have been harmed by a software error causing their insulin pumps to spontaneously shut down, the Food and Drug Administration announced in a recall notice on Wednesday.

The product is made by Tandem Diabetes Care, which sells touchscreen insulin pumps and an accompanying app to help dose the medicine. Around 300,000 people use the technology. Tandem found that a bug in the app’s software is causing the app to repeatedly crash and relaunch, draining the insulin pump’s battery through unnecessary Bluetooth communication.

An insulin pump shutting down unexpectedly could kill people, especially if the shutdown occurs while the person is sleeping. There have been no reports of death so far, the FDA said. Tandem users commiserated over the issue on Reddit two months ago, with one user describing waking up at 2 a.m. to a dead pump. “Infuriating,” the user wrote. “Absolutely should be sending a notice out to all customers about this.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

entertainment

WSS

NIH documents show early flaws of $1.6 billion long Covid program

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Readout Newsletter: New research from Sanofi, Regeneron, etc.

ASCO: Palliative care found as helpful given virtually as in person

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Telehealth options flood the market as retailers push virtual care

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA has safety concerns on CRISPR

New air purifier tech could be key to improving indoor air quality

WHO may add ‘noma' to its list of neglected tropical diseases

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Cancer drug shortages should be causing more outrage

Traditional Chinese medicine benefits explored in new JAMA study

Alkermes shareholders re

Cassava reveals details — and problems — with Alzheimer's study

focus

FDA's Pazdur wants cancer trials to range beyond China alone

How to increase colonoscopy rates? Looks like an AI can help

Biden's order seeks to regulate AI risk without stifling innovation

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

HIV drugs protect against transmission, even in unprotected sex

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

hotspot

leisure time

entertainment

explore